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Abstract
Background: The carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) acts as a receptor for adherent-
invasive E. coli (AIEC) and its ileal expression is increased in patients with Crohn’s disease (CD). Given its contribution to the
pathogenesis of CD, we aimed to investigate the role of genetic variants in the CEACAM6 region in patients with
inflammatory bowel diseases (IBD).
Methodology: In this study, a total of 2,683 genomic DNA samples (including DNA from 858 CD patients, 475 patients with
ulcerative colitis (UC), and 1,350 healthy, unrelated controls) was analyzed for eight CEACAM6 SNPs (rs10415946,
rs1805223=p.Pro42Pro, rs4803507, rs4803508, rs11548735=p.Gly239Val, rs7246116=pHis260His, rs2701, rs10416839). In
addition, a detailed haplotype analysis and genotype-phenotype analysis were performed. Overall, our genotype analysis
did not reveal any significant association of the investigated CEACAM6 SNPs and haplotypes with CD or UC susceptibility,
although certain CEACAM6 SNPs modulated CEACAM6 expression in intestinal epithelial cell lines. Despite its function as
receptor of AIEC in ileal CD, we found no association of the CEACAM6 SNPs with ileal or ileocolonic CD. Moreover, there was
no evidence of epistasis between the analyzed CEACAM6 variants and the main CD-associated NOD2, IL23R and ATG16L1
variants.
Conclusions: This study represents the first detailed analysis of CEACAM6 variants in IBD patients. Despite its important role
in bacterial attachment in ileal CD, we could not demonstrate a role for CEACAM6 variants in IBD susceptibility or regarding
an ileal CD phenotype. Further functional studies are required to analyze if these gene variants modulate ileal bacterial
attachment.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
inflammatory bowel diseases (IBD), characterized by an aberrant
mucosal immune response to bacteria-derived antigens in the gut of
genetically susceptible hosts [1,2]. Although the exact pathogenesis of
IBD still remains unsolved, current evidence indicates that defective
T-cellapoptosis [3] and autophagy [4,5,6,7] as wellas an impairment
of intestinal epithelial barrier function [8,9] play important roles. This
hypothesis is strengthened by data from genetic association studies
identifying CD susceptibility genes involved in innate immunity and
bacterial recognition (NOD2/CARD15) [10,11], and from genome-
wide association studies(GWAS),whichidentified susceptibilitygenes
involved in autophagy (ATG16L1, IRGM) [4,5] and the proinflam-
matory IL-23/Th17 pathway [12].
While a specific causative pathogen in IBD has not been found so
far[13,14],investigationsoftheregulatorymechanismsoperatingat
the mucosal level suggest that regulatory cells reactive to the
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19319commensal intestinal microflora might play a role in cross-reactive
protection toward different bacterial antigens [15]. Moreover, there
is raising evidence for a major role of certain bacteria such as
adherent-invasive E. coli (AIEC) in ileal CD [16,17,18]. Interest-
ingly, the carcinoembryonic antigen-related cell adhesion molecule
6 (CEACAM6) has recently shown to act as a receptor for AIEC,
supporting ileal bacterial colonization as a major pathomechanism
in CD [19]. The carcinoembryonic antigen (CEA) family consists of
two subfamilies, the CEACAM subgroup and the pregnancy
specific glycoprotein (PSG) subgroup [20,21]. CEACAM family
members were found to be expressed in epithelial, endothelial, and
hematopoietic cells, including T-lymphocytes, natural killer (NK)
cells, dendritic cells (DC) and neutrophils. They may also be useful
as biomarkers in cancer since they are often over-expressed in
ovarian, endometrial, breast, lung, and colon carcinomas
[21,22,23]. Depending on the tissue involved, CEACAMs are
transmitting signals that result in a variety of effects including
regulation of the cell cycle, tumor suppression, angiogenesis,
lymphocyte activation and adhesion [22,23,24,25,26,27,28,29].
CEACAM1, CEACAM5, and CEACAM6 represent three of the
CEACAM subfamily members expressed in intestinal epithelial
cells. There is increased expression of CEACAM5 and CEACAM6
at the apical surface of the ileal epithelium in CD patients [19].
Moreover,ileallesionsinCDpatientswerefoundtobe colonized by
pathogenic AIEC [19], strengthening the hypothesis that an
abnormal intestinal expression of CEACAM6 in CD patients is
associated with an increased colonization of AIEC via type 1 pili
expression inducing gut inflammation [18]. AIEC adhere to and
invadeintestinalepithelialcells[30] resultinginAIECaccumulation
in macrophages leading to high amounts of TNF-a [31], thereby
perpetuating intestinal inflammation.
Given the potential implication of dysfunctional CEACAM6
expression in the pathogenesis of IBD, we aimed to analyze the role
of CEACAM6 SNPs in IBD susceptibility. A total of eight single
nucleotide polymorphisms (SNPs) were analyzed in a large German
cohort of CD and UC patients. Five SNPs in the CEACAM6 region
(rs10415946, rs4803507, rs4803508, rs2701, rs10416839) were
selected from the data of the international HapMap project
covering the CEACAM6 gene plus 10 kB flanking the centromeric
and telomeric end of the gene, respectively. Additional selection
criteria for the SNPs were a minor allele frequency of at least 5%
and a r
2 of 1. The SNPs rs4803507 and rs4803508 are localized in
intron 2, rs2701 is localized within exon 6 encoding the 39-
untranslated region, while the SNPs rs10415946 and rs10416839
are within the 59-a n dt h e3 9-flanking region, respectively.
Additionally, the coding variants rs1805223=p.Pro42Pro (exon
2), rs11548735=p.Gly239Val and rs7246116=pHis260His (exon
4) were investigated for which allele frequencies are published und
which display a minor allele frequency of at least 5% in the
Caucasianpopulation. The structure of the CEACAM6 gene and the
localization of the SNPs investigated in the presented study are
shown in figure 1. Considering the abnormal expression of
CEACAM6 in the ileal epithelium of CD patients and its role as
receptor for ileal AIEC [19], we also analyzed for a potential
association with an ileal CD phenotype and investigated potential
gene-gene interactions with the NOD2 gene, which has been shown
to be a strong predictor of ileal CD, as well as with other CD
susceptibility genes such as IL23R and ATG16L1.
Materials and Methods
Ethics statement
The study was approved by the local Ethics committee of the
Ludwig-Maximilians-University of Munich (Department of Med-
icine) and adhered to the ethical principles for medical research
involving human subjects of the Helsinki Declaration. Prior to the
study, we obtained written, informed consent from all patients
included.
Study population and characterization of disease
phenotype
The study population comprised 858 patients with CD, 475
patients with UC, and 1350 healthy, unrelated controls of
Caucasian origin. The study was approved by the local Ethics
committee of the Ludwig-Maximilians-University of Munich
(Department of Medicine) and adhered to the ethical principles
for medical research involving human subjects of the Helsinki
Declaration. Prior to the study, we obtained written, informed
consent from all patients included. The phenotypic assessment was
performed blind to the results of the genotypic data and included
demographic data and clinical parameters (behaviour and
anatomic location of IBD, disease-related complications, previous
surgery or immunosuppressive therapy) which were recorded by
investigation of patient charts and a detailed questionnaire. The
diagnosis of CD or UC was based on established international
guidelines including endoscopic, radiological, and histopatholog-
ical criteria [32,33]. Patients with CD were assessed according to
the Montreal classification [33] based on age at diagnosis (A),
location (L), and behaviour (B) of disease. In patients with UC,
anatomic location was also assessed in accordance to the Montreal
classification [33], using the criteria ulcerative proctitis (E1), left-
sided UC (distal UC; E2), and extensive UC (pancolitis; E3).
Patients with indeterminate colitis were excluded from the study.
The demographic and phenotypic data of the IBD study
population are summarized in Table 1.
DNA extraction and genotyping of the CEACAM6 variants
Blood samples were taken from all participants of the study and
genomic DNA was isolated from peripheral blood leukocytes using
the DNA blood mini kit from Qiagen (Hilden, Germany)
Figure 1. Exon-intron structure of the CEACAM6 gene and relative positions of single nucleotide polymorphisms (SNPs) investigated
in the presented study. This figure represents the genomic structure of the CEACAM6 gene consisting of 6 exons and indicates the positions of the
CEACAM6 SNPs studied. The SNPs rs4803507 and rs4803508 are localized in intron 2, rs2701 is localized in exon 6 encoding the 39-untranslated
region, while the SNPs rs10415946 and rs10416839 are within the 59-a n dt h e3 9-flanking region, respectively. The coding variant
rs1805223=p.Pro42Pro is located in exon 2, while rs11548735=p.Gly239Val and rs7246116=pHis260His are located in exon 4. The grey part of
exons 1 represents the 59 untranslated region, the grey part of exons 5 and exon 6 represent the 39 untranslated region.
doi:10.1371/journal.pone.0019319.g001
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(rs10415946, rs1805223=p.Pro42Pro, rs4803507, rs4803508,
rs11548735=p.Gly239Val, rs7246116=pHis260His, rs2701,
rs10416839) were genotyped by PCR and melting curve analysis
using a pair of fluorescence resonance energy transfer (FRET)
probes in a LightCyclerH 480 Instrument (Roche Diagnostics,
Mannheim, Germany) as described in previous studies [34,35,36].
The total volume of the PCR was 5 ml containing 25 ng of
genomic DNA, 16 Light Cycler 480 Genotyping Master Mix
(Roche Diagnostics), 2.5 pmol of each primer and 0.75 pmol of
each FRET probe (TIB MOLBIOL, Berlin, Germany). In the case
of rs1805223, rs4803507 and rs4803508, the concentration of the
forward primer, and in the case of rs10415946 and rs2701, the
concentration of the reverse primer, were reduced to 1.25 pmol.
Two SNPs were analyzed in a multiplex reaction, the combina-
tions were: rs10415946+rs4803508, rs1805223+rs4803507,
rs11548735+rs7246116 and rs2701+rs10416839. For the combi-
nation rs11548735+rs7246116 only one primer pair was used. The
PCR comprised an initial denaturation step (95uC for 10 min) and
45 cycles (95uC for 10uC sec, 60 for 10 sec, 72uC for 15 sec).
Details on the melting curve analysis and on the PCR used for
sequencing were published in previous studies [34,35,36]. The
PCR products were purified using the QIAquick PCR Purification
Kit (Qiagen) and sequenced by a commercial sequencing company
(Sequiserve, Vaterstetten, Germany). All sequences of primers
and FRET probes and primer annealing temperatures used
for genotyping and for sequence analysis are given in Tables 2
and 3.
Table 1. Demographic and phenotypic disease characteristics of the study population.
Crohn’s disease
n=858
Ulcerative colitis
n=475
Controls
n=1350
Gender
Male (%) 45.3 47.9 62.6
Female (%) 54.7 52.5 37.4
Age (yrs)
Mean 6 SD 40.2613.2 42.4614.4 45.8610.7
Range 11–81 7–86 18–71
Body mass index
Mean 6 SD 23.164.2 23.964.1
Range 13–40 15–41
Age at diagnosis (yrs)
Mean 6 SD 27.7611.8 32.0613.3
Range 1–78 9–81
Disease duration (yrs)
Mean 6 SD 11.968.6 10.567.7
Range 0–44 1–40
Positive family history of IBD (%) 16.0 16.1
Disease localization (Crohn’s disease)
n=764*
L1 (ileal) 113
L2 (colonic) 97
L3 (ileocolonic) 554
+ L4 (upper GI)** 88
Disease behaviour (Crohn’s disease)
n=754*
B1 (non-stricturing, non-penetrating) 187
B2 (stricturing) 208
B3 (penetrating) 359
Disease extent (Ulcerative colitis)
n=260*
E1 (proctitis) 24
E2 (left-sided UC) 96
E3 (pancolitis) 140
Disease localization and disease behaviour for Crohn’s disease and the disease extent in ulcerative colitis are given according to the Montreal classification of
inflammatory bowel diseases.
*Given is the number of patients for which the corresponding disease phenotype information was available.
**Additional upper GI involvement.
doi:10.1371/journal.pone.0019319.t001
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variants p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066845),
and p.Leu1007fsX1008 (rs2066847) were available from previous
studies [34,37]. Similarly, for epistasis analysis genotype data for
the main CD-associated IL23R variants (rs1004819, rs7517847,
rs10489629, rs2201841, rs11465804, rs11209026 (p.Arg381Gln),
rs1343151, rs10889677, rs11209032, rs1495965) and ATG16L1
SNPs (rs13412102, rs12471449, rs6431660, rs1441090,
rs2289472, rs2241880 (p.Thr300Ala), rs2241879, rs3792106,
rs4663396) were available from previous studies [34–36].
RNA isolation and quantitative PCR
Total RNA was isolated from five intestinal epithelial cell (IEC)
lines (DLD-1, HCT116, HT-29, SW480, T84) as indicated with
the Qiagen RNeasy Kit and was reverse transcribed using Roche
Transcriptor First Strand cDNA Synthesis Kit. Quantitative PCR
was performed with SYBR Green PCR Master Mix from Roche
on a LightCycler480 instrument. The following primers were used
for amplification: CEACAM6 forward 59-CACAACCTGCCCCA-
GAATCGTAT-39; CEACAM6 reverse 59-TTGGGCAGCT-
CCGGGTATACATG-39; b-actin forward 59-GCCAACCGCGA-
GAAGATGA-39; b-actin reverse 59-CATCACGATGCCAG-
TGGTA-39. b-actin expression was used to normalize gene
expression in the respective samples.
Statistical analyses
Each genetic marker was tested for Hardy-Weinberg equilib-
rium in the three subgroups of the study population. Fisher’s exact
test was used for comparison between categorical variables, while
Student’s t test was applied for quantitative variables. Single-
marker allelic tests were performed with Pearson’s x
2 test. All tests
were two-tailed, considering p-values,0.05 as significant. Odds
ratios were calculated for the minor allele at each SNP. For
multiple comparisons, Bonferroni correction was applied where
Table 2. Primer sequences (F: forward primer, R: reverse Primer) and FRET probe sequences used for genotyping of CEACAM6
variants.
Polymorphism Primer sequences FRET probe sequences
rs10415946 F: AGCCCTGGATGTGTCCAC
A: AGTCCCTGGGGTCCTCAA
TGGATTTACCCCCAGCAAG-FL
LC670-AGGTCACAGAGATGTTTGGGGTCCTAG
rs1805223=p.Pro42Pro F: CCACCCTAATGCATAGGTCC
A: CGATTCTGTGGCAGGTTGT
GAATCCACGCCATTCAATG-FL
LC670-CGCAGAGGGGAAGGAGGTTCTTC
rs4803507 F: GCATCGTTCCTTCCTTTATGTA
A: TTTTTCCATAAGTGGAGATCGTT
GAATTCACAACACACCTAAACC-FL
LC640-AGTATGTTATCAAGAAAAATACTACTTCCAGCCC
rs4803508 F: CCTGTCCCCCTCACTGTCT
A: TTTTTCCATAAGTGGAGATCGTT
CTGCTGAAAGATCCAATCCC-FL
LC610-GCCAGGCTGCACAGTATCCTTGGG
rs11548735=p.Gly239Val F: TGGTTGAGACTTCAGGGTTGT
A: TATGGGCTTGGCACATATAGG
CCCAGATGTCCCCACCAT-FL
LC610-TCCCCCTCAAAGGCCAATTACCGTC
rs7246116=pHis260His F: TGGTTGAGACTTCAGGGTTGT
A: TATGGGCTTGGCACATATAGG
CCTGCCACGCAGCCTCTA-FL
LC670-CCCACCTGCACAGTACTCTTGGTTTATCAA
rs2701 F: AAGATGTCAAAACAAGACTCCTCA
A: AAGTCCAACTCTGAAAAGGACC
CAAGATAGATCTGACACTCTGTTAAGT-FL
LC610-ACCCTCTGAAGCTACTTCTTGTGAAATACT
rs10416839 F: CTTTCAGTTATATGTTGGCTCACTT
A: AAAAACACAGCATTATAGATCAACAG
CCAGTGGCAGTTTCCTCTG-FL
LC640-TGTAGTCTGAATCAGGTGTACAACTGAGCC
Note: FL: Fluorescein, LC610: LightCycler-Red 610; LC640: LightCycler-Red 640. The polymorphic position within the sensor probe is underlined. A phosphate is linked to
the 39-end of the acceptor probe to prevent elongation by the DNA polymerase in the PCR.
doi:10.1371/journal.pone.0019319.t002
Table 3. Primer sequences used for the sequence analysis of the CEACAM6 variants.
Polymorphism Primer sequences
rs10415946 TGCAGAAAGAACAATTCAGAATCTTA
CTTGGGTCTGTCAGCACC
rs1805223=p.Pro42Pro GGGTGAAGAGACCTGCTCAG
CGCCTTTGTACCAGCTGTAAC
rs4803507 ACGTTGCTTCTAATTTGGCA
GAAAAGTTTGTCAGGAGTTTAGACC
rs4803508 CCTGTCCCCCTCACTGTCT
ATGGGTGATGATGGGACTTC
rs11548735=p.Gly239Val, rs7246116=pHis260His TGGTTGAGACTTCAGGGTTGT
TATGGGCTTGGCACATATAGG
rs2701 AAGATGTCAAAACAAGACTCCTCA
AGAACAGGTGAGTCTAGAAGTCCA
rs10416839 CTTTCAGTTATATGTTGGCTCACTT
AAAAACACAGCATTATAGATCAACAG
doi:10.1371/journal.pone.0019319.t003
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SNP Minor allele
Crohn’s disease
n=858
Ulcerative colitis
n=475
Controls
n=1350
HapMap-CEU**
n=120
MAF/HWE p value OR [95% CI] MAF/HWE p value OR [95% CI] MAF/HWE MAF
rs10415946 G 0.383/0.506 0.21 1.08 [0.96–1.23] 0.338/0.113 0.16 0.89 [0.76–1.04] 0.364/0.906 0.440
rs1805223=p.Pro42Pro A 0.309/0.679 0.21 1.09 [0.95–1.24] 0.264/0.235 0.12 0.87 [0.74–1.03] 0.291/0.262 0.342
rs4803507 A 0.307/0.803 0.24 1.08 [0.96–1.24] 0.269/0.454 0.26 0.90 [0.76–1.06] 0.290/0.234 0.280
rs4803508 A 0.377/0.266 0.25 0.95 [0.84–1.08] 0.406/0.622 0.35 1.07 [0.92–1.25] 0.389/0.606 0.358
rs11548735=p.Gly239Val T 0.399/0.885 0.62 0.97 [0.86–1.10] 0.422/1 0.44 1.06 [0.92–1.24] 0.407/0.612 0.422
rs7246116=pHis260His T 0/* 1.00 - 0.001/1 0.26 - 0/* unknown
rs2701 G 0.401/0.942 0.62 0.97 [0.85–1.09] 0.423/0.903 0.47 1.06 [0.91–1.23] 0.409/0.778 0.408
rs10416839 T 0.359/0.653 0.24 1.08 [0.95–1.23] 0.371/1 0.11 1.14 [0.97–1.32] 0.341/0.545 0.292
Minor allele frequencies (MAF), p-value for deviation from Hardy-Weinberg equilibrium (HWE), allelic test P-values, and odds ratios (OR, shown for the minor allele) with
95% confidence intervals (CI) are depicted for both the CD and UC case-control cohorts. Measurements for linkage disequilibrium (LD) are provided in Tables 11, 12 and
13.
*monomorphic SNP.
**The MAFs in the HapMap-CEU population (=Utah residents with Northern and Western European ancestry) are derived from the NCBI SNP database (available under
http://www.ncbi.nlm.nih.gov/snp).
doi:10.1371/journal.pone.0019319.t004
Table 5. Haplotypes of CEACAM6 SNPs in Crohn’s disease (CD) case-control sample and omnibus p-values for association with CD
susceptibility.
Haplotype combination omnibus p-value
rs10415946-rs1805223 0.46
rs1805223-rs4803507 0.40
rs4803507-rs4803508 0.84
rs4803508-rs11548735 0.63
rs11548735-rs7246116 0.85
rs7246116-rs2701 0.78
rs2701-rs10416839 0.36
rs10415946-rs1805223-rs4803507 0.40
rs1805223-rs4803507-rs4803508 0.58
rs4803507-rs4803508-rs11548735 0.74
rs4803508-rs11548735-rs7246116 0.63
rs11548735-rs7246116-rs2701 0.74
rs7246116-rs2701-rs10416839 0.36
rs10415946-rs1805223-rs4803507-rs4803508 0.48
rs1805223-rs4803507-rs4803508-rs11548735 0.67
rs4803507-rs4803508-rs11548735-rs7246116 0.75
rs4803508-rs11548735-rs7246116-rs2701 0.39
rs11548735-rs7246116-rs2701-rs10416839 0.38
rs10415946-rs1805223-rs4803507-rs4803508-rs11548735 0.70
rs1805223-rs4803507-rs4803508-rs11548735-rs7246116 0.67
rs4803507-rs4803508-rs11548735-rs7246116-rs2701 0.59
rs4803508-rs11548735-rs7246116-rs2701-rs10416839 0.21
rs10415946-rs1805223-rs4803507-rs4803508-rs11548735-rs7246116 0.70
rs1805223-rs4803507-rs4803508-rs11548735-rs7246116-rs2701 0.66
rs4803507-rs4803508-rs11548735-rs7246116-rs2701-rs10416839 0.39
rs10415946-rs1805223-rs4803507-rs4803508-rs11548735-rs7246116-rs2701 0.77
rs1805223-rs4803507-rs4803508-rs11548735-rs7246116-rs2701-rs10416839 0.41
rs10415946-rs1805223-rs4803507-rs4803508-rs11548735-rs7246116-rs2701-rs10416839 0.39
Given are the omnibus p-values for the CEACAM6 haplotype combinations regarding CD susceptibility.
doi:10.1371/journal.pone.0019319.t005
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susceptibility.
Haplotype combination omnibus p-value
rs10415946-rs1805223 0.50
rs1805223-rs4803507 0.60
rs4803507-rs4803508 0.73
rs4803508-rs11548735 0.50
rs11548735-rs7246116 0.65
rs7246116-rs2701 0.55
rs2701-rs10416839 0.60
rs10415946-rs1805223-rs4803507 0.50
rs1805223-rs4803507-rs4803508 0.82
rs4803507-rs4803508-rs11548735 0.73
rs4803508-rs11548735-rs7246116 0.37
rs11548735-rs7246116-rs2701 0.69
rs7246116-rs2701-rs10416839 0.60
rs10415946-rs1805223-rs4803507-rs4803508 0.81
rs1805223-rs4803507-rs4803508-rs11548735 0.83
rs4803507-rs4803508-rs11548735-rs7246116 0.58
rs4803508-rs11548735-rs7246116-rs2701 0.50
rs11548735-rs7246116-rs2701-rs10416839 0.54
rs10415946-rs1805223-rs4803507-rs4803508-rs11548735 0.87
rs1805223-rs4803507-rs4803508-rs11548735-rs7246116 0.76
rs4803507-rs4803508-rs11548735-rs7246116-rs2701 0.55
rs4803508-rs11548735-rs7246116-rs2701-rs10416839 0.39
rs10415946-rs1805223-rs4803507-rs4803508-rs11548735-rs7246116 0.87
rs1805223-rs4803507-rs4803508-rs11548735-rs7246116-rs2701 0.75
rs4803507-rs4803508-rs11548735-rs7246116-rs2701-rs10416839 0.48
rs10415946-rs1805223-rs4803507-rs4803508-rs11548735-rs7246116-rs2701 0.87
rs1805223-rs4803507-rs4803508-rs11548735-rs7246116-rs2701-rs10416839 0.49
rs10415946-rs1805223-rs4803507-rs4803508-rs11548735-rs7246116-rs2701-rs10416839 0.82
Given are the omnibus p-values for the CEACAM6 haplotype combinations regarding UC susceptibility.
doi:10.1371/journal.pone.0019319.t006
Table 7. Associations of CEACAM6 gene markers with the anatomic location of Crohn’s disease (CD) according to the Montreal
classification [33].
Anatomic
location rs10415946
rs1805223=
p.Pro42Pro rs4803507 rs4803508
rs11548735=
p.Gly239Val
rs7246116=
pHis260His rs2701 rs10416839
L1 (ileal)
n=113
0.320 0.321 0.559 0.876 0.961 * 0.997 0.566
L2 (colonic)
n=97
0.854 0.988 0.970 0.611 0.751 * 0.684 0.580
L3 (ileocolonic)
n=554
0.451 0.759 0.803 0.425 0.684 * 0.691 0.114
Any ileal
involvement
(L1+L3)
n=667
0.373 0.586 0.689 0.620 0.771 * 0.744 0.117
P-values are depicted for the CD case-control cohorts.
*There were no carriers of the minor allele of rs7146116 in the CD and control cohort.
doi:10.1371/journal.pone.0019319.t007
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tested using logistic regression in R using the number of minor
alleles as predictor variable, therefore implementing an Armitage
test of trend. Data were evaluated by using the SPSS 13.0 software
(SPSS Inc., Chicago, IL, USA) and R-2.4.1. (http://cran.r-project.
org). For haplotype analysis, PLINK v 1.06 (http://pngu.mgh.
harvard.edu/,purcell/plink/) was used running a sliding window
approach with variation of the window size from 2 to 8 included
markers and using the option ‘‘hap-logistic’’. Linkage disequilib-
rium (LD) was also analyzed using PLINK.
Results
CEACAM6 variants are not associated with IBD
susceptibility
The genotyping success rates were at least 99% for all eight
SNPs tested and were comparable between the controls and the
CD and UC patients groups. In all three subgroups (CD, UC, and
controls), the allele frequencies of the CEACAM6 SNPs
rs10415946, rs1805223=p.Pro42Pro, rs4803507, rs4803508,
rs11548735=p.Gly239Val, rs7246116=p.His260His, rs2701,
rs10416839 were in accordance with the predicted Hardy-
Weinberg equilibrium (Table 4). Overall, we observed no
significant differences in the frequencies of the investigated
CEACAM6 SNPs in CD and UC patients compared to healthy
controls (Table 4) implicating no significant association of
CEACAM6 variants and IBD susceptibility. Only two patients
(both with UC) were minor allele carriers of the rare CEACAM6
SNP rs7246116=p.His260His, therefore not allowing a compar-
ative analysis of this SNP regarding CD susceptibility.
CEACAM6 haplotypes are not associated with CD and UC
susceptibility
Considering recent evidence showing that certain CEACAM6
haplotypes modulate susceptibility to bacterial infections [38], we
next performed a detailed haplotype analysis in our IBD cohort.
However, as shown in Tables 5 and 6, we could not demonstrated
significant associations of CEACAM6 haplotypes with CD and UC
susceptibility.
The CEACAM6 variants are not associated with an ileal
disease phenotype in CD patients
Since CEACAM6 has recently shown to act as a receptor for
AIEC, thereby promoting bacterial colonization in ileal CD [19],
we further investigated whether CEACAM6 SNPs are associated
with ileal disease in CD patients. Based on a phenotype analysis
according to the Montreal classification of IBD [33], the detailed
phenotypic data available from a subcohort of 667 CD patients was
analyzed for disease localization. None of the investigated
CEACAM6 SNPs was associated with ileal or ileocolonic CD
Table 8. Analysis for gene-gene interactions between CEACAM6 and NOD2 variants regarding susceptibility to Crohn’s disease
(CD).
CEACAM6
SNPs
NOD2 SNPs rs10415946 rs1805223 rs4803507 rs4803508 rs11548735 rs7246116 rs2701 rs10416839
rs2066844 p.Arg702Trp 0.56 0.37 0.39 0.31 0.62 * 0.65 0.77
rs2066845 p.Gly908Arg 0.06 0.28 0.28 0.54 0.35 * 0.43 0.58
rs2066847 p.Leu1007fsX1008 0.93 0.80 0.97 0.51 0.71 * 0.56 0.82
p-values for epistasis analysis between CEACAM6 and NOD2 SNPs in the CD case-control sample.
*There were no carriers of the minor allele of rs7146116 in the CD and control cohort.
doi:10.1371/journal.pone.0019319.t008
Table 9. Analysis for gene-gene interaction with CEACAM6.and IL23R variants regarding susceptibility to Crohn’s disease (CD).
CEACAM6
SNPs
IL23R SNPs rs10415946 rs1805223 rs4803507 rs4803508 rs11548735 rs7246116 rs2701 rs10416839
rs1004819 0.13 0.31 0.29 0.50 0.46 * 0.52 0.95
rs7517847 0.67 0.20 0.31 0.17 0.23 * 0.27 0.81
rs10489629 0.64 0.09 0.11 0.97 0.79 * 0.71 0.98
rs2201841 0.52 0.42 0.40 0.61 0.50 * 0.46 0.63
rs11465804 0.20 0.13 0.19 0.59 0.26 * 0.32 0.76
rs11209026 0.08 0.05 0.08 0.35 0.28 * 0.35 0.91
rs1343151 0.35 0.04 0.06 0.83 0.57 * 0.60 0.64
rs10889677 0.55 0.48 0.44 0.77 0.66 * 0.62 0.51
rs11209032 0.43 0.52 0.53 0.87 0.99 * 0.89 0.19
rs1495965 0.47 0.66 0.58 0.73 0.61 * 0.84 0.32
p-values for epistasis between CEACAM6.and IL23R SNPs in the CD case-control sample. After Bonferroni correction, the association highlighted in bold did not remain
significant.
*There were no carriers of the minor allele of rs7146116 in the CD and control cohort.
doi:10.1371/journal.pone.0019319.t009
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(CD).
CEACAM6
SNPs
ATG16L1 SNPs rs10415946 rs1805223 rs4803507 rs4803508 rs11548735 rs7246116 rs2701 rs10416839
rs13412102 0.89 0.89 0.72 0.89 0.55 * 0.55 0.79
rs12471449 0.49 0.44 0.40 0.74 0.58 * 0.56 0.04
rs6431660 0.53 0.66 0.50 0.87 0.98 * 0.93 0.66
rs1441090 0.56 0.32 0.26 0.78 0.89 * 0.95 0.27
rs2289472 0.67 0.65 0.49 0.67 0.86 * 0.83 0.57
rs2241880 0.84 0.74 0.57 0.64 0.81 * 0.83 0.58
rs2241879 0.93 0.81 0.68 0.74 0.73 * 0.72 0.56
rs3792106 0.67 0.52 0.44 0.50 0.69 * 0.73 0.83
rs4663396 0.81 0.93 0.80 0.56 0.85 * 0.90 0.15
p-values for epistasis between CEACAM6 and ATGT16L1 SNPs in the CD case-control sample. After Bonferroni correction, the association highlighted in bold did not
remain significant.
*There were no carriers of the minor allele of rs7146116 in the CD and control cohort.
doi:10.1371/journal.pone.0019319.t010
Figure 2. Analysis of CEACAM6 gene expression and CEACAM6 gene variants in intestinal epithelial cell (IEC) lines. (A) Total RNA isolated
fromIEClinesasindicatedwasreversetranscribedandwasanalyzedforCEACAM6geneexpressionbyquantitativePCR.T84cellsexpressCEACAM6atthe
highest level followed by HT-29 cells, and intermediate CEACAM6 expression was found in SW480 and DLD-1 cells. CEACAM6 expression was close to the
detection limit after 40 PCR cycles in HCT116 cells (note the logarithmic scale onthe y-axis). CEACAM6 expression was normalized to b-actin expression in
the respective cDNA samples. (B) Genomic DNA was isolated from IEC lines and 8 SNPs in CEACAM6 were analyzed as indicated by DNA sequencing. The
respective alleles for these SNPs in each cell line are depicted in the table. This analysis revealed that T84, the cell line with the highest CEACAM6
expression, and HCT116 cells, the cell line with the lowest CEACAM6 expression, are the only IEC lines with unique genotypes for certain CEACAM6 SNPs
(depicted in bold italic). DLD-1 and SW480 cells have identical genotypes for all SNPs analyzed and nearly identical CEACAM6 expression levels.
doi:10.1371/journal.pone.0019319.g002
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has limited power to detect weak disease associations. For example,
based on 667 patients with a L1/L3 disease phenotype, a minor
allele frequency of 0.40 and an OR of 1.1, the power is 28.88% to
detect an effect on a significance level of 5% (Genetic Power
Calculator, http://pngu.mgh.harvard.edu/,purcell/gpc/).
Analysis for gene-gene interaction with CD-associated
NOD2, IL23R and ATG16L1 variants
Given the raising evidence for a key role of CEACAM6 in the
complex interaction of the mucosal immune system and intestinal
bacteria, we next analyzed for potential epistasis between CEACAM6
SNPs (rs10415946, rs1805223=p.Pro42Pro, rs4803507, rs4803508,
rs11548735=p.Gly239Val, rs7246116=pHis260His, rs2701, rs10-
416839) and the three main CD-associated NOD2/CARD15
variants p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066845), and
p.Leu1007fsX1008 (rs2066847) which have previously shown to be
strongly associated with CD and ileal disease localization. However,
there was no evidence for epistasis between the CEACAM6 SNPs and
the three analyzed NOD2/CARD15 variants (Table 8).
Recently, we demonstrated an association of the IL23R SNP
rs1004819 (TT homozygous carriers) with ileal CD [34].
Therefore, we also analyzed for potential gene-gene interaction
between CEACAM6 SNPs and the major CD-associated IL23R
variants. However, we did not find evidence for epistasis between
CEACAM6 and IL23R regarding CD susceptibility (Table 9).
In addition, novel findings indicate a major role for ATG16L1 in
Paneth cell development in the terminal ileum. Therefore, we also
analyzed for potential epistasis between the CEACAM6 SNPs and
the major CD-associated ATG16L1 SNPs. However, we were also
unable to demonstrate evidence for epistasis between these two
genes (Table 10).
p-values for epistasis between CEACAM6 and ATGT16L1 SNPs
in the CD case-control sample. After Bonferroni correction, the
association highlighted in bold did not remain significant.
*There were no carriers of the minor allele of rs7146116 in the
CD and control cohort.
CEACAM6 genotypes modulate CEACAM6 expression in
intestinal epithelial cell lines
To analyze a potential influence of CEACAM6 gene variants on
CEACAM6 gene expression, we determined CEACAM6 mRNA
levels in five intestinal epithelial cell (IEC) lines DLD-1, HCT116,
HT-29, SW480 and T84 by quantitative PCR. This analysis
revealed considerable differences in CEACAM6 expression
depending on the cell line. While T84 cells showed the highest
expression, the expression in HCT116 cells was four orders of
magnitude smaller and close to the detection limit (Fig. 2A).
SW480 and DLD-1 cells showed similar, intermediate expression
(Fig. 2A). Interestingly, when these cell lines were analyzed for
CEACAM6 gene variants, only T84 and HCT116 cells, the two cell
lines with the highest and lowest CEACAM6 expression,
respectively, had unique genotype variants when compared with
the other cell lines (Fig. 2B). While T84 cells were the only cells
that had a unique genotype for rs10415946 and
rs1805223=p.Pro42Pro, HCT116 had a unique genotype in
SNPs rs11548735=p.Gly239Val, rs2701 and rs10416839. SW480
and DLD-1 cells had identical CEACAM6 genotypes and their
CEACAM6 expression was nearly identical (Fig. 2A and 2B). A
detailed analysis regarding linkage disequilibrium between the
investigated CEACAM6 SNPs stratified for CD, UC and controls is
given in Tables 11, 12 and 13.
Discussion
In summary, our study represents the first detailed analysis of
CEACAM6 SNPs regarding disease susceptibility and phenotypic
consequences in IBD patients. Compared to previous GWAS, our
study had a more complete coverage of the CEACAM6 gene region
(see details in Table 14). Overall, we did not observe a significant
influence of the investigated CEACAM6 SNPs on CD and UC
susceptibility. Moreover, a detailed haplotype analysis did not
reveal significant associations with IBD susceptibility. CEACAM6
has recently shown to act as a receptor for AIEC suggesting an
important role in bacterial colonization of the ileal mucosa in CD
patients [19]. However, none of the investigated CEACAM6 SNPs
was associated with ileal or ileocolonic CD.
Interestingly, a recent study demonstrated that the defect in
CEACAM family members in intestinal epithelial cells isolated
from CD patients appears to be related to the aberrant nuclear
localization of the transcription factor SOX9 [39] which regulates
cell proliferation and is required for Paneth cell differentiation in
Table 11. Analysis for linkage disequilibrium between
CEACAM6 SNPs in patients with Crohn’s disease.
rs10415946 rs4803507 rs4803508 rs2701 rs10416839
rs10415946 ** * * *
rs4803507 0.65/0.96 * * * *
rs4803508 0.12/0.58 0.09/0.59 * * *
rs2701 0.12/0.53 0.10/0.57 0.80/0.95 * *
rs10416839 ,0.01/0.03 ,0.01/0.13 0.25/0.85 0.31/0.90 *
Values are given as r
2/D9-measurements.
doi:10.1371/journal.pone.0019319.t011
Table 12. Analysis for linkage disequilibrium between
CEACAM6 SNPs in patients with ulcerative colitis.
rs10415946 rs4803507 rs4803508 rs2701 rs10416839
rs10415946 ** * * *
rs4803507 0.70/0.98 * * * *
rs4803508 0.15/0.65 0.11/0.67 * * *
rs2701 0.14/0.61 0.10/0.60 0.87/0.97 * *
rs10416839 ,0.01/0.09 ,0.01/0.11 0.29/0.89 0.33/0.91 *
Values are given as r
2/D9-measurements.
doi:10.1371/journal.pone.0019319.t012
Table 13. Analysis for linkage disequilibrium between
CEACAM6 SNPs in controls.
rs10415946 rs4803507 rs4803508 rs2701 rs10416839
rs10415946 ** * * *
rs4803507 0.68/0.98 * * * *
rs4803508 0.15/0.63 0.09/0.60 * * *
rs2701 0.14/0.60 0.09/0.57 0.81/0.94 * *
rs10416839 0.01/0.12 ,0.01/0.06 0.23/0.84 0.29/0.90 *
Values are given as r
2/D9-measurements.
doi:10.1371/journal.pone.0019319.t013
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ized by a specific decrease in Paneth cell alpha-defensins and
defective Paneth cell-mediated host defense [42] which has been
linked to the NOD2 genotype [43], although this finding is opposed
by the results of a recent study [44], and additional modifiers of
Paneth cell function such as XBP1 are involved [45]. Therefore,
one might speculate whether the role of CEACAM6 in ileal
bacterial colonization is regulated via SOX9 expression implicat-
ing defective Paneth cell function in patients with small bowel CD.
Given the association of defensin secretion with the NOD2
genotype [43] and the findings of numerous previous studies
including studies from our IBD center demonstrating ileal disease
localization in CD patients with NOD2 mutations [37,46,47], we
also tested for potential gene-gene interaction of CEACAM6 and
NOD2. However, we found no evidence for epistasis between these
two genes regarding CD susceptibility. Further functional studies
analyzing the complex interaction of intestinal CEACAM6
expression and bacterial adherence in the gut particularly of CD
patients carrying CEACAM6 variants will therefore be required.
Given the important role of ATG16L1 in Paneth cell development
of the terminal ileum and the role of IL23R in the development of
proinflammatory Th17 cells, we also analyzed for epistasis of these
two genes with CEACAM6 but were unable to find evidence for
significant epistasis of these genes regarding CD susceptibility.
Interestingly, a recent study indicated that CEACAM6 and a
regulatory element near the 39 end of CEACAM3 are associated
with disease severity in patients with cystic fibrosis [48]. However,
a previous study in IBD patients suggested that heterozygous
carriers of the DF508 mutation in the CFTR gene, the main
susceptibility gene for patients with cystic fibrosis, might exert a
protective effect in CD [49], suggesting opposing effects of genetic
risk loci for cystic fibrosis and IBD.
In the meta-analysis of Barrett et al. [50], a SNP (rs4807569)
within the chromosomal region 19q13, in which the CEACAM6
gene is located, was weakly associated with CD, but this
association could not be confirmed in a replication cohort. In
the recent meta-analysis of Franke et al. [51], two SNPs (rs
736289 and rs281376) within this region were strongly
associated with CD. However, thed i s t a n c eb e t w e e nt h e s eS N P s
and the CEACAM6 gene is 9 and 7 megabases, respectively, and
thus, the disease causing variant within this region remains to be
identified.
CEACAM6 is also a major target gene for Smad3-mediated
TGF-b signaling [52]. Since Smad3 differentially regulates the
induction of regulatory and inflammatory Th17 cell differentiation
[53], which are key players in the IBD pathogenesis [54], further
investigations analyzing Th17 cell differentiation in IBD patients
carrying CEACAM6 variants might also be of high interest.
Moreover, very recent evidence from studies in mice demonstrated
that colonization of the small intestine with a single commensal
microbe, segmented filamentous bacterium (SFB), is sufficient to
induce Th17 cells in the lamina propria [55]. These SFB adhere
tightly to the surface of epithelial cells in the terminal ileum of
mice with Th17 cells but are absent from mice that have few Th17
cells [55]. Further studies will have to characterize if SFB
adherence is mediated (similar to AIEC adherence) by CEACAM
family members.
In summary, we performed the first systemic analysis of
CEACAM6 gene variants in IBD patients. Despite the great
importance of CEACAM6 as receptor for AIEC on the ileal
mucosa of CD patients, we were unable to demonstrate a specific
role of CEACAM6 variants in IBD susceptibility. Furthermore,
there was no evidence for an association with ileal CD or for
epistasis with NOD2, IL23R, and ATG16L1 variants in CD
susceptibility. Further functional studies will be necessary to
elucidate how CEACAM6 gene variants may modulate bacterial
colonization in IBD patients. Even if this study was unable to find
a role for CEACAM6 gene variants in IBD susceptibility, the
CEACAM6 protein is likely to be an important mediator of the
pathogenesis of CD [56].
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